Skip to main content

Advertisement

Table 4 Multivariate survival analysis in subgroups of cases regarding TMZ therapy

From: Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy

Variable TMZ therapy No TMZ therapy
  HR 95% CI P value HR 95% CI P value
Gender 0.45 0.12-1.25 0.08 1.82 0.76-4.06 0.12
Age 1.12 1.01-1.16 0.005 1.10 0.98-1.14 0.03
Performance status 0.97 0.90-1.02 0.006 0.99 0.92-1.04 0.01
Extent of surgery 1.05 0.98-1.12 0.003 1.02 0.96-1.18 0.01
MGMT promoter 5.85 1.86-18.02 0.001 1.25 0.62-2.34 0.74
SLC22A18 Protein expression 5.65 1.79-17.45 0.002 1.12 0.56-2.28 0.62